Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies. Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches that seek to improve patient outcomes and provide new tools for clinicians in combating cancer.